chr2-240878862-C-A

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000030.3(AGXT):​c.*41C>A variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.37 in 1,530,324 control chromosomes in the GnomAD database, including 108,657 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.31 ( 8132 hom., cov: 33)
Exomes 𝑓: 0.38 ( 100525 hom. )

Consequence

AGXT
NM_000030.3 3_prime_UTR

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts U:1B:4

Conservation

PhyloP100: -2.35

Publications

17 publications found
Variant links:
Genes affected
AGXT (HGNC:341): (alanine--glyoxylate aminotransferase) This gene is expressed only in the liver and the encoded protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification. Mutations in this gene, some of which alter subcellular targetting, have been associated with type I primary hyperoxaluria. [provided by RefSeq, Jul 2008]
AGXT Gene-Disease associations (from GenCC):
  • alanine glyoxylate aminotransferase deficiency
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • primary hyperoxaluria type 1
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Myriad Women’s Health, Ambry Genetics, Labcorp Genetics (formerly Invitae), Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 2-240878862-C-A is Benign according to our data. Variant chr2-240878862-C-A is described in ClinVar as Benign. ClinVar VariationId is 204063.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.395 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
AGXTNM_000030.3 linkc.*41C>A 3_prime_UTR_variant Exon 11 of 11 ENST00000307503.4 NP_000021.1 P21549

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
AGXTENST00000307503.4 linkc.*41C>A 3_prime_UTR_variant Exon 11 of 11 1 NM_000030.3 ENSP00000302620.3 P21549
AGXTENST00000470255.1 linkn.998C>A non_coding_transcript_exon_variant Exon 3 of 3 2

Frequencies

GnomAD3 genomes
AF:
0.308
AC:
46763
AN:
152020
Hom.:
8136
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.152
Gnomad AMI
AF:
0.409
Gnomad AMR
AF:
0.263
Gnomad ASJ
AF:
0.286
Gnomad EAS
AF:
0.255
Gnomad SAS
AF:
0.279
Gnomad FIN
AF:
0.430
Gnomad MID
AF:
0.285
Gnomad NFE
AF:
0.399
Gnomad OTH
AF:
0.303
GnomAD2 exomes
AF:
0.332
AC:
52992
AN:
159740
AF XY:
0.338
show subpopulations
Gnomad AFR exome
AF:
0.151
Gnomad AMR exome
AF:
0.242
Gnomad ASJ exome
AF:
0.294
Gnomad EAS exome
AF:
0.261
Gnomad FIN exome
AF:
0.417
Gnomad NFE exome
AF:
0.404
Gnomad OTH exome
AF:
0.357
GnomAD4 exome
AF:
0.377
AC:
520050
AN:
1378184
Hom.:
100525
Cov.:
26
AF XY:
0.377
AC XY:
256909
AN XY:
682282
show subpopulations
African (AFR)
AF:
0.144
AC:
4580
AN:
31724
American (AMR)
AF:
0.252
AC:
9073
AN:
36066
Ashkenazi Jewish (ASJ)
AF:
0.291
AC:
7279
AN:
25048
East Asian (EAS)
AF:
0.240
AC:
8842
AN:
36850
South Asian (SAS)
AF:
0.302
AC:
23910
AN:
79254
European-Finnish (FIN)
AF:
0.418
AC:
18169
AN:
43514
Middle Eastern (MID)
AF:
0.287
AC:
1627
AN:
5666
European-Non Finnish (NFE)
AF:
0.401
AC:
426332
AN:
1062480
Other (OTH)
AF:
0.351
AC:
20238
AN:
57582
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.506
Heterozygous variant carriers
0
18288
36576
54865
73153
91441
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
13072
26144
39216
52288
65360
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.307
AC:
46762
AN:
152140
Hom.:
8132
Cov.:
33
AF XY:
0.306
AC XY:
22731
AN XY:
74366
show subpopulations
African (AFR)
AF:
0.152
AC:
6322
AN:
41528
American (AMR)
AF:
0.262
AC:
4012
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.286
AC:
991
AN:
3470
East Asian (EAS)
AF:
0.254
AC:
1310
AN:
5154
South Asian (SAS)
AF:
0.278
AC:
1339
AN:
4824
European-Finnish (FIN)
AF:
0.430
AC:
4552
AN:
10590
Middle Eastern (MID)
AF:
0.282
AC:
83
AN:
294
European-Non Finnish (NFE)
AF:
0.399
AC:
27141
AN:
67954
Other (OTH)
AF:
0.303
AC:
640
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1592
3184
4776
6368
7960
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
460
920
1380
1840
2300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.358
Hom.:
12091
Bravo
AF:
0.292
Asia WGS
AF:
0.284
AC:
991
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Uncertain:1Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Primary hyperoxaluria, type I Uncertain:1Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Nov 27, 2014
Clinical Biochemistry Laboratory, Health Services Laboratory
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:research

- -

Jul 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Aug 07, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.87
CADD
Benign
1.0
DANN
Benign
0.49
PhyloP100
-2.3
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.0
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4273214; hg19: chr2-241818279; COSMIC: COSV56755073; COSMIC: COSV56755073; API